Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his new column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his new column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Advaxis CEO Tom Moore Discovers A New Way To Fight Cancer
OneMedRadio interviewed Tom Moore, CEO and Chairman of the Board of Directors of Advaxis [OTC:ADXS]. He discusses the company’s novel immunotherapy technology.
The Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Verisante Technologies Detects Skin Cancer in Less Than A Second
OneMedRadio interviewed Thomas Braun, CEO of Verisante Technologies [CVE:VRS], a medical device company committed to commercializing innovative systems for the early detection of cancer.
Financings and business developments in the global diagnostics business
Biocept, Inc., a privately-held CLIA-certified laboratory testing company, and Clarient, Inc. (a GE Healthcare Company) say that they will be collaborating on the commercialization of a proprietary blood test for circulating tumor cells…
ThermoGenesis Sees Explosive Growth Opportunities in Stem Cells
Mel Engle, CEO of ThermoGenesis [NASDAQ: KOOL] recently discussed with OneMedRadio, the company’s stem cell products and FDA approval that may have groundbreaking implications for the stem cell market.
